Life sciences investor Casdin Capital significantly increased its position in early cancer detection company GRAIL (GRAL), more than doubling its share count to 480,000. The trade, valued at an estimated $17.07 million, boosted the firm's reported holding to $32.77 million as of the end of the second quarter. This update is based on a quarterly 13F filing from mid-August, which discloses trades that occurred in the prior quarter, so it may not reflect the firm's current holdings.
GRAIL is known for its Galleri blood test, which is designed to detect multiple types of cancer before symptoms appear. The company has been advancing its clinical validation and recently announced an upcoming FDA advisory committee meeting for the test. Casdin Capital specializes in the life sciences and healthcare sectors, with a stated focus on investing in companies that leverage genomics, data, and technology to transform medicine.